Ken Griffin Novo Cure LTD Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novo Cure LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 210,900 shares of NVCR stock, worth $4.02 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
210,900
Previous 167,300
26.06%
Holding current value
$4.02 Million
Previous $2.61 Million
140.4%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding NVCR
# of Institutions
290Shares Held
75.6MCall Options Held
1.77MPut Options Held
538K-
Black Rock Inc. New York, NY12.1MShares$231 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$225 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA8.87MShares$169 Million0.05% of portfolio
-
Capital World Investors Los Angeles, CA4.82MShares$91.8 Million0.02% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.74MShares$52.2 Million5.68% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...